Myocardial Infarction

Video Library

  • Running time: 35 minutes, 49 seconds

     

    00.16 Lp(a) structure and metabolism

    01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases

    02.38 Factors influencing Lp(a) level

    03.35 Physiological functions of Lp(a)

    04.12 Atherogenicity of Lp(a)

    04.56 Clinical implication of Lp(a) elevation

    05.25 Genetic variants associated with increased Lp(a) concentrations

    05.44 Association between high Lp(a) level and risk of various cardiovascular diseases

    07.43 Clinical implication of Lp(a) elevation at low LDL-C

    08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors

    09.40 Is reducing Lp(a) physiologically safe?

    10.34 Strategies to lower Lp(a) level

    11.57 Future directions in Lp(a) research

    12.37 Summary

    Video Library

    Lp(a):What is it and its role in atherosclerosis

    In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

    View

  • Video Library

    Lipid measurements in the management of cardiovascular diseases

    In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

    View
View All Myocardial Infarction Video Library

Articles

View All Myocardial Infarction Articles

Case Studies

  • Case Studies

    August 2023

    Take this short quiz to test your knowledge on the recently published debate on dyslipidemias titled “Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers”.

    CLICK HERE TO VIEW THE DEBATE.

    Eur Heart J. 2023 Jul 1;44(25):2292-2304. doi: 10.1093/eurheartj/ehad275

    Take

  • Case Studies

    Quiz of the month – June 2022

    Take our patient case study quiz specially curated for you by our Faculty Member, Prof. Chern-En Chiang.

    Case Study: A 67-year-old male comes to the ER with the complaint of excruciating anterior chest pain for 1-hour. The parameters measured in the ER are as follows:

     

    Vital parameters

    Blood pressure: 146/78 mm Hg

    Heart rate: 92/min

    Respiratory rate: 16/min

     

    ECG shows ST elevation over V1-V3, suggesting acute anterior MI, and pathological Q waves over leads II, III and aVF. Toponin I was 15.40 ng/mL. Urgent coronary angiograph shows total occlusion over LAD-M, patent left main, patent left circumflex, and 80% stenosis over RCA-M. Left ventriculogram showing moderate hypokinesis over anterior septal area and mild hypokinesis over inferior wall with an EF of 44%. Primary PCI with 2 DES over LAD-M and RCA-M was performed uneventfully.

     

    Past history

    Inferior myocardial infarction 4 years with medical treatment

    HT for more than 10 years with regular treatment

    Type 2 diabetes for 8 years

    Denied smoking

    Obesity with a BMI of 30.5

     

    Lab data

    Na 134 meq/L, K 4.2 meq/L

    Cr 1.05 mg/dL, eGFR 73 mL/min (CKD-EPI),

    UACR 350 mg/g

    ALT 32 mg/dL

    HbA1c 8.3%

    LDL-C 98 mg/dL, HDL-C 28 mg/dL, triglyceride 259 mg/dL

    Toponin I 15.40 ng/mL, hs-CRP 18.2 mg/dL

    Lp(a) 83 mg/dL [upper limit of normal Lp(a) = 30 mg/dL] 

     

    Medication history
    before admission

    Amlodipine 5 mg OD, valsartan 160 mg OD, bisoprolol 5 mg OD

    Metformin 850 mg BD

    Aspirin 81 mg OD

    Atorvastatin 20 mg OD

     

    Investigation

    Acute MI after successful PCI, and this is a second MI (previous inferior MI)

    Post-MI LV dysfunction (LVEF of 44%)

    Uncontrolled diabetes (HbA1c 8.3%)

    Suboptimal control of lipid levels (LDL-C 98 mg/dL)

    A very high level of Lp(a) (83 mg/dL)

    Take